Abstract
Triple-negative breast cancer (TNBC) and malignant melanoma are highly aggressive cancers that widely express the cell surface chondroitin sulfate proteoglycan 4 (CSPG4/NG2). CSPG4 plays an important role in tumor cell growth and survival and promotes chemo- and radiotherapy resistance, suggesting that CSPG4 is an attractive target in cancer therapy. In the present work, we applied the drug delivery technology photochemical internalization (PCI) in combination with the novel CSPG4-targeting immunotoxin 225.28-saporin as an efficient and specific strategy to kill aggressive TNBC and amelanotic melanoma cells. Light-activation of the clinically relevant photosensitizer TPCS2a (fimaporfin) and 225.28-saporin was found to act in a synergistic manner, and was superior to both PCI of saporin and PCI-no-drug (TPCS2a + light only) in three TNBC cell lines (MDA-MB-231, MDA-MB-435 and SUM149) and two BRAFV600E mutated malignant melanoma cell lines (Melmet 1 and Melmet 5). The cytotoxic effect was highly dependent on the light dose and expression of CSPG4 since no enhanced cytotoxicity of PCI of 225.28-saporin compared to PCI of saporin was observed in the CSPG4-negative MCF-7 cells. The PCI of a smaller, and clinically relevant CSPG4-targeting toxin (scFvMEL-rGel) validated the CSPG4-targeting concept in vitro and induced a strong inhibition of tumor growth in the amelanotic melanoma xenograft A-375 model. In conclusion, the combination of the drug delivery technology PCI and CSPG4-targeting immunotoxins is an efficient, specific and light-controlled strategy for the elimination of aggressive cells of TNBC and malignant melanoma origin. This study lays the foundation for further preclinical evaluation of PCI in combination with CSPG4-targeting.
Similar content being viewed by others
References
B. D. Lehmann, J. A. Bauer, X. Chen, M. E. Sanders, A. B. Chakravarthy, Y. Shyr and J. A. Pietenpol, J. Clin. Invest., 2011, 121, 2750–2767.
R. Dent, M. Trudeau, K. I. Pritchard, W. M. Hanna, H. K. Kahn, C. A. Sawka, L. A. Lickley, E. Rawlinson, P. Sun and S. A. Narod, Clin. Cancer Res., 2007, 13, 4429–4434.
S. Irshad, P. Ellis and A. Tutt, Curr. Opin. Oncol., 2011, 23, 566–577.
K. B. Reddy, Curr. Oncol., 2011, 18, e173–e179.
O. Gluz, C. Liedtke, N. Gottschalk, L. Pusztai, U. Nitz and N. Harbeck, Ann. Oncol., 2009, 20, 1913–1927.
V. Gray-Schopfer, C. Wellbrock and R. Marais, Nature, 2007, 445, 851–857.
M. F. Avril, S. Aamdal, J. J. Grob, A. Hauschild, P. Mohr, J. J. Bonerandi, M. Weichenthal, K. Neuber, T. Bieber, K. Gilde, V. Guillem Porta, J. Fra, J. Bonneterre, P. Saiag, D. Kamanabrou, H. Pehamberger, J. Sufliarsky, J. L. Gonzalez Larriba, A. Scherrer and Y. Menu, J. Clin. Oncol., 2004, 22, 1118–1125.
K. T. Flaherty, F. S. Hodi and D. E. Fisher, Nat. Rev. Cancer, 2012, 12, 349–361.
R. Nazarian, H. Shi, Q. Wang, X. Kong, R. C. Koya, H. Lee, Z. Chen, M. K. Lee, N. Attar, H. Sazegar, T. Chodon, S. F. Nelson, G. McArthur, J. A. Sosman, A. Ribas and R. S. Lo, Nature, 2010, 468, 973–977.
F. S. Hodi, S. J. O'Day, D. F. McDermott, R. W. Weber, J. A. Sosman, J. B. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J. C. Hassel, W. Akerley, A. J. van den Eertwegh, J. Lutzky, P. Lorigan, J. M. Vaubel, G. P. Linette, D. Hogg, C. H. Ottensmeier, C. Lebbe, C. Peschel, I. Quirt, J. I. Clark, J. D. Wolchok, J. S. Weber, J. Tian, M. J. Yellin, G. M. Nichol, A. Hoos and W. J. Urba, N. Engl. J. Med., 2010, 363, 711–723.
C. Robert, L. Thomas, I. Bondarenko, S. O'Day, J. Weber, C. Garbe, C. Lebbe, J. F. Baurain, A. Testori, J. J. Grob, N. Davidson, J. Richards, M. Maio, A. Hauschild, W. H. Miller Jr., P. Gascon, M. Lotem, K. Harmankaya, R. Ibrahim, S. Francis, T. T. Chen, R. Humphrey, A. Hoos and J. D. Wolchok, N. Engl. J. Med., 2011, 364, 2517–2526.
M. Campoli, S. Ferrone and X. Wang, Adv. Cancer Res., 2010, 109, 73–121.
M. R. Campoli, C. C. Chang, T. Kageshita, X. Wang, J. B. McCarthy and S. Ferrone, Crit. Rev. Immunol., 2004, 24, 267–296.
M. A. Price, L. E. Colvin Wanshura, J. Yang, J. Carlson, B. Xiang, G. Li, S. Ferrone, A. Z. Dudek, E. A. Turley and J. B. McCarthy, Pigm. Cell Melanoma Res., 2011, 24, 1148–1157.
J. Legg, U. B. Jensen, S. Broad, I. Leigh and F. M. Watt, Development, 2003, 130, 6049–6063.
X. Wang, T. Osada, Y. Wang, L. Yu, K. Sakakura, A. Katayama, J. B. McCarthy, A. Brufsky, M. Chivukula, T. Khoury, D. S. Hsu, W. T. Barry, H. K. Lyerly, T. M. Clay and S. Ferrone, J. Natl. Cancer Inst., 2010, 102, 1496–1512.
M. Al-Hajj, M. S. Wicha, A. Benito-Hernandez, S. J. Morrison and M. F. Clarke, Proc. Natl. Acad. Sci. U. S. A., 2003, 100, 3983–3988.
K. Berg, P. K. Selbo, L. Prasmickaite, T. E. Tjelle, K. Sandvig, J. Moan, G. Gaudernack, O. Fodstad, S. Kjolsrud, H. Anholt, G. H. Rodal, S. K. Rodal and A. Hogset, Cancer Res., 1999, 59, 1180–1183.
P. K. Selbo, A. Weyergang, A. Hogset, O. J. Norum, M. B. Berstad, M. Vikdal and K. Berg, J. Controlled Release, 2010, 148, 2–12.
L. Polito, M. Bortolotti, D. Mercatelli, M. G. Battelli and A. Bolognesi, Toxins, 2013, 5, 1698–1722.
P. K. Selbo, G. Sivam, O. Fodstad, K. Sandvig and K. Berg, Int. J. Cancer, 2000, 87, 853–859.
K. Lund, M. Bostad, E. Skarpen, M. Braunagel, S. Kiprijanov, S. Krauss, A. Duncan, A. Hogset and P. K. Selbo, mAbs, 2014, 6, 1038–1050.
W. L. Yip, A. Weyergang, K. Berg, H. H. Tonnesen and P. K. Selbo, Mol. Pharmaceutics, 2007, 4, 241–251.
A. Weyergang, P. K. Selbo and K. Berg, J. Controlled Release, 2006, 111, 165–173.
M. B. Berstad, A. Weyergang and K. Berg, Biochim. Biophys. Acta, 2012, 1820, 1849–1858.
A. Weyergang, P. K. Selbo, M. E. Berstad, M. Bostad and K. Berg, Lasers Surg. Med., 2011, 43, 721–733.
E. W. Stratford, M. Bostad, R. Castro, E. Skarpen, K. Berg, A. Hogset, O. Myklebost and P. K. Selbo, Biochim. Biophys. Acta, 2013, 1830, 4235–4243.
M. Bostad, K. Berg, A. Hogset, E. Skarpen, H. Stenmark and P. K. Selbo, J. Controlled Release, 2013, 168, 317–326.
M. Bostad, C. E. Olsen, Q. Peng, K. Berg, A. Hogset and P. K. Selbo, J. Controlled Release, 2015, 206, 37–48.
M. Bostad, M. Kausberg, A. Weyergang, C. E. Olsen, K. Berg, A. Hogset and P. K. Selbo, Mol. Pharm., 2014, 11, 2764–2776.
P. K. Selbo, M. G. Rosenblum, L. H. Cheung, W. Zhang and K. Berg, PLoS One, 2009, 4, e6691, DOI: 10.1371/journal. pone.0006691.
P. K. Selbo, A. Weyergang, A. Bonsted, S. G. Bown and K. Berg, J. Pharmacol. Exp. Ther., 2006, 319, 604–612.
P. J. Lou, P. S. Lai, M. J. Shieh, A. J. MacRobert, K. Berg and S. G. Bown, Int. J. Cancer, 2006, 119, 2692–2698.
P. K. Selbo, A. Weyergang, M. S. Eng, M. Bostad, G. M. Mælandsmo, A. Hogset and K. Berg, J. Controlled Release, 2012, 159, 197–203.
C. E. Olsen, A. Weyergang, V. T. Edwards, K. Berg, A. Brech, S. Weisheit, A. Høgset and P. K. Selbo, Biochem. Pharmacol., 2017, 144, 63–77.
P. K. Selbo, M. Bostad, C. E. Olsen, V. T. Edwards, A. Hogset, A. Weyergang and K. Berg, Photochem. Photobiol. Sci., 2015, 14, 1433–1450.
A. A. Sultan, W. Jerjes, K. Berg, A. Hogset, C. A. Mosse, R. Hamoudi, Z. Hamdoon, C. Simeon, D. Carnell, M. Forster and C. Hopper, Lancet Oncol., 2016, 1217–1229, DOI: 10.1016/S1470-2045(16)30224-8.
A. F. Chambers, Cancer Res., 2009, 69, 5292–5293.
A. K. Croker and A. L. Allan, Breast Cancer Res. Treat., 2012, 133, 75–87.
W. W. Hwang-Verslues, W. H. Kuo, P. H. Chang, C. C. Pan, H. H. Wang, S. T. Tsai, Y. M. Jeng, J. Y. Shew, J. T. Kung, C. H. Chen, E. Y. Lee, K. J. Chang and W. H. Lee, PLoS One, 2009, 4, e8377.
J. R. Ohlfest, D. M. Zellmer, J. Panyam, S. K. Swaminathan, S. Oh, N. N. Waldron, S. Toma and D. A. Vallera, Drug Delivery Transl. Res., 2013, 3, 195–204.
K. L. van Golen, S. Davies, Z. F. Wu, Y. Wang, C. D. Bucana, H. Root, S. Chandrasekharappa, M. Strawderman, S. P. Ethier and S. D. Merajver, Clin. Cancer Res., 1999, 5, 2511–2519.
L. Prasmickaite, N. Skrbo, H. K. Hoifodt, Z. Suo, O. Engebraten, H. P. Gullestad, S. Aamdal, O. Fodstad and G. M. Maelandsmo, Pigm. Cell Melanoma Res., 2010, 23, 449–451.
J. M. Rae, C. J. Creighton, J. M. Meck, B. R. Haddad and M. D. Johnson, Breast Cancer Res. Treat., 2007, 104, 13–19.
B. S. Wilson, K. Imai, P. G. Natali and S. Ferrone, Int. J. Cancer, 1981, 28, 293–300.
X. Wang, A. Katayama, Y. Wang, L. Yu, E. Favoino, K. Sakakura, A. Favole, T. Tsuchikawa, S. Silver, S. C. Watkins, T. Kageshita and S. Ferrone, Cancer Res., 2011, 71, 7410–7422.
M. G. Rosenblum, L. H. Cheung, Y. Liu and J. W. Marks III, Cancer Res., 2003, 63, 3995–4002.
N. A. Franken, H. M. Rodermond, J. Stap, J. Haveman and C. van Bree, Nat. Protoc., 2006, 1, 2315–2319.
G. G. Steel and M. J. Peckham, Int. J. Radiat. Oncol., Biol., Phys., 1979, 5, 85–91.
P. K. Selbo, O. Kaalhus, G. Sivam and K. Berg, Photochem. Photobiol., 2001, 74, 303–310.
A. Weyergang, M. E. Berstad, B. Bull-Hansen, C. E. Olsen, P. K. Selbo and K. Berg, Photochem. Photobiol. Sci., 2015, 14, 1465–1475.
V. Nygaard, L. Prasmickaite, K. Vasiliauskaite, T. Clancy and E. Hovig, Oncoscience, 2014, 1, 82–94.
J. Muller, O. Krijgsman, J. Tsoi, L. Robert, W. Hugo, C. Song, X. Kong, P. A. Possik, P. D. Cornelissen-Steijger, M. H. Geukes Foppen, K. Kemper, C. R. Goding, U. McDermott, C. Blank, J. Haanen, T. G. Graeber, A. Ribas, R. S. Lo and D. S. Peeper, Nat. Commun., 2014, 5, 5712.
K. S. Hoek and C. R. Goding, Pigm. Cell Melanoma Res., 2010, 23, 746–759.
M. C. Zipser, O. M. Eichhoff, D. S. Widmer, N. C. Schlegel, N. L. Schoenewolf, D. Stuart, W. Liu, H. Gardner, P. D. Smith, P. Nuciforo, R. Dummer and K. S. Hoek, Pigm. Cell Melanoma Res., 2011, 24, 326–333.
D. J. Konieczkowski, C. M. Johannessen, O. Abudayyeh, J. W. Kim, Z. A. Cooper, A. Piris, D. T. Frederick, M. Barzily-Rokni, R. Straussman, R. Haq, D. E. Fisher, J. P. Mesirov, W. C. Hahn, K. T. Flaherty, J. A. Wargo, P. Tamayo and L. A. Garraway, Cancer Discovery, 2014, 4, 816–827.
Y. H. Hung, L. M. Chen, J. Y. Yang and W. Y. Yang, Nat. Commun., 2013, 4, 2111.
Z. Rivera, S. Ferrone, X. Wang, S. Jube, H. Yang, H. I. Pass, S. Kanodia, G. Gaudino and M. Carbone, Clin. Cancer Res., 2012, 18, 5352–5363.
A. Svendsen, J. J. Verhoeff, H. Immervoll, J. C. Brogger, J. Kmiecik, A. Poli, I. A. Netland, L. Prestegarden, J. Planaguma, A. Torsvik, A. B. Kjersem, P. O. Sakariassen, J. I. Heggdal, W. R. Van Furth, R. Bjerkvig, M. Lund-Johansen, P. O. Enger, J. Felsberg, N. H. Brons, K. J. Tronstad, A. Waha and M. Chekenya, Acta Neuropathol., 2011, 122, 495–510.
J. Wang, A. Svendsen, J. Kmiecik, H. Immervoll, K. O. Skaftnesmo, J. Planaguma, R. K. Reed, R. Bjerkvig, H. Miletic, P. O. Enger, C. B. Rygh and M. Chekenya, PLoS One, 2011, 6, e23062.
X. Zheng, J. L. Carstens, J. Kim, M. Scheible, J. Kaye, H. Sugimoto, C. C. Wu, V. S. LeBleu and R. Kalluri, Nature, 2015, 527, 525–530.
T. M. Phillips, W. H. McBride and F. Pajonk, J. Natl. Cancer Inst., 2006, 98, 1777–1785.
W. A. Woodward, B. G. Debeb, W. Xu and T. A. Buchholz, Cancer, 2010, 116, 2840–2845.
C. M. Fillmore and C. Kuperwasser, Breast Cancer Res., 2008, 10, R25.
A. Prat, J. S. Parker, O. Karginova, C. Fan, C. Livasy, J. I. Herschkowitz, X. He and C. M. Perou, Breast Cancer Res., 2010, 12, R68.
D. Kessel, P. Thompson, K. Saatio and K. D. Nantwi, Photochem. Photobiol., 1987, 45, 787–790.
K. Berg, S. Nordstrand, P. K. Selbo, D. T. Tran, E. Angell-Petersen and A. Hogset, Photochem. Photobiol. Sci., 2011, 10, 1637–1651.
A. P. Castano, P. Mroz and M. R. Hamblin, Nat. Rev. Cancer, 2006, 6, 535–545.
M. Hâkerud, P. K. Selbo, Y. Waeckerle-Men, E. Contassot, P. Dziunycz, T. M. Kundig, A. Hogset and P. Johansen, J. Controlled Release, 2015, 198, 10–17.
M. Hâkerud, Y. Waeckerle-Men, P. K. Selbo, T. M. Kundig, A. Høgset and P. Johansen, J. Controlled Release, 2014, 174, 143–150.
T. Haug, G. Brede, M. Hâkerud, A. G. Nedberg, O. A. Gederaas, T. H. Flo, V. Edwards, P. K. Selbo, A. Hogset and O. Halaas, Front. Immunol., DOI: 10.3389/fimmu.2018.00650, in press.
Y. Y. Huang, D. Vecchio, P. Avci, R. Yin, M. Garcia-Diaz and M. R. Hamblin, Biol. Chem., 2013, 394, 239–250.
Acknowledgements
We thank Nina Iversen at the Department of Medical Genetics (Division of Diagnostics and Intervention, Oslo University Hospital) for providing the SUM149 cell line. We also thank the Flow Cytometry Core Facility (Institute for Cancer Research) by Idun D. Rein and Kirsti S. Landsverk for the assistance with flow cytometry analyses, Kotryna Seip for the technical assistance with the Melmet cell lines and Solveig Pettersen for help with the immunofluorescence. We thank the Norwegian Radium Hospital Research Foundation (FU 0803), the Norwegian Research Council (SFI-CAST) for funding this project.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Eng, M.S., Kaur, J., Prasmickaite, L. et al. Enhanced targeting of triple-negative breast carcinoma and malignant melanoma by photochemical internalization of CSPG4-targeting immunotoxins. Photochem Photobiol Sci 17, 539–551 (2018). https://doi.org/10.1039/c7pp00358g
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1039/c7pp00358g